oral iron polysaccharide 150 mg twice daily for 16 weeks Control: Matching placebo Stable HFREF outpatients with ID Mortality Permanent study drug discontinuation Adverse events Serious adverse Study reported several outcomes (peak walk test distance and Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments NYHA class II-IV LVEF 40% Hb between 9 and 15 g/dL (men) or 9 and (women) Study duration: events Change in peak Change in 6 minute walk test distance Change in KCCQ clinical summary score KCCQ) as median and IQR Toblli (Toblli ) Intervention: Weekly infusions of IV iron (iron sucrose) equivalent to 200 mg iron for 5 weeks Control: Matching placebo (saline solution) N = 60 HF outpatients with ID, anaemia and CKD NYHA class II-IV LVEF 35% creatinine ml/min Hb <12.5 g/dl for men and <11.5 g/dl for women Mortality Quality of life (MLWHFQ) HF hospitalisations Exercise tolerance Change in haemoglobin Abdominal pain Nausea Systolic blood pressure patients recruited and analysis published. patients recruited subsequently and second analysis published on full dataset. Study duration: Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 52: Clinical evidence summary: IV iron versus placebo Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Intravenous iron (95% CI) months VERY LOWa,b due to risk of bias, imprecision (from 31 fewer to 34 more) Quality of life EQ5D. Scale from: 0 to 1. HIGH The mean change in quality of life in the control groups was The mean quality of life in the intervention groups was Quality of life EQ5D VAS. 